This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1) and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 541380 and the business size standard is $14.0 million.

Only one (1) award will be made as a result of this solicitation. This will be awarded as an Indefinite Delivery, Indefinite Quantity contract with firm fixed price task orders issued as needed. Period of performance is one (1) base year and (1) option year.

It has been determined there are no opportunities to acquire green products or services for this procurement.

HPV is the cause of cervical cancer, as well as subsets of cancers at other anatomic sites, including the oropharynx, vulva/vagina, penis, and anus. We recently reported that HPV16 E6 seropositivity was present in prediagnostic samples for 34.8% of oropharyngeal cancer cases and 0.6% of controls. The increased risk of oropharyngeal cancer among HPV16 E6 seropositive participants was independent of time between blood collection and diagnosis and was observed more than 10 years before diagnosis. NCI now aims to confirm its initial finding by testing additional samples from other studies, and to expand its research to anogenital cancers, in order to understand whether this potential cancer biomarker is unique to HPV-driven oropharyngeal cancer, or also predicts risk at other anatomic sites where HPV is known to be a causal factor.

The purpose of the procurement is to provide HPV laboratory testing to support NCI-IARC (International Agency for Research on Cancer) collaborative case-control study. This study has four (4) aims:

Confirm the main effects of HPV on cancer at several anatomic sites of the head and neck

Expand evaluation to cancers of the anogenital region

Investigate the specificity of the marker in people without cancer

Evaluate the sensitivity of the marker by comparing it to the gold-standard of HPV in corresponding tumor samples.

Deutsches Krebsforschungszentrum/German Cancer Research Center is testing the tumor samples from cases in the NCI's Europe cohort study. It is necessary that the tumors from the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) study be tested using the exact same methodology and platforms as those used for the European cohort so that the same so the results are interpretable across the studies. Further, pathology archive samples from these cohort studies do not have access to fresh frozen tissue-instead, only formalin-fixed paraffin-embedded (FFPE) is available. Deutsches Krebsforschungszentrum/German Cancer Research Center is the only known lab to our knowledge.

This notice is not a request for competitive quotation. However, if any interested party, especially small businesses, believes it can meet the above requirement, it may submit a capability statement, proposal, or quotation, which shall be considered by the agency. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 5:00 PM EST, on March 11, 2016. All responses and questions must be in writing and faxed 240-276-5401 or emailed to Kimesha Leake, Contract Specialist via electronic mail at [email protected]. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must be registered and have valid certification in the System for Award Management (SAM) through sam.gov. Reference: N02CO62520-24-01 on all correspondence.